Analysis supports using adjuvant over neoadjuvant ADT with RT for localized prostate cancer
November 25th 2020At a median follow-up of 15 years, the pooled analysis showed statistically significant improvements with adjuvant ADT over neoadjuvant ADT in biochemical failure, distant metastasis, and progression-free survival rates.
Pembrolizumab, nadofaragene firadenovec lead the charge in BCG-unresponsive NMIBC
November 9th 2020“There is an urgent need for novel therapies in BCG-unresponsive disease. While standard cystectomy is highly curative, it is associated with a substantial risk for morbidity and non-trivial mortality,” said Arjun Balar MD.
Can cryopreserved umbilical cord allograft improve post-RARP continence recovery?
October 29th 2020A new trial is exploring whether CLARIX CORD 1K, a cryopreserved umbilical cord allograft, can contribute to a faster return of erectile function and urinary continence after robot-assisted radical prostatectomy.
Radiotracer fluciclovine (18F) PET leads to improved cancer control in recurrent prostate cancer
October 27th 2020EMPIRE-1 is the first randomized trial to demonstrate an improvement in failure-free survival with treatment based on advanced molecular imaging versus conventional imaging in men with recurrent prostate cancer.